Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence

Trial Profile

Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2018 According to a Galena Biopharma media release, data from this study has been submitted for presentation at a major medical conference that will take place during the second half of 2018.
    • 01 Jun 2018 Status changed from active, no longer recruiting to discontinued, according to the Sellas Life Sciences Group media release.
    • 02 Apr 2018 Interim data presented in a Sellas Life Sciences Group Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top